Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine + Ramucirumab in CEACAM5+ Gastric/GEJ Cancer
NCT05071053Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tusamitamab ravtansine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sanofi. Started Nov 2021; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05071053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071053.